ZX 8177
Alternative Names: ZX-8177Latest Information Update: 05 Jun 2023
Price :
$50 *
At a glance
- Originator Nanjing Zenshine Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical in Cancer presented at the 114th Annual Meeting of the American Association for Cancer ResearchSession (AACR-2023)
- 02 Mar 2023 Nanjing Zenshine Pharmaceuticals plans clinical trial in Solid tumours in 2023 (Nanjing Zenshine Pharmaceuticals pipeline, February 2023)
- 08 Apr 2022 Preclinical trials in Solid tumours in China (unspecified route)